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a  b  s  t  r  a  c  t
Development  of  safe and efﬁcacious  vaccines  whose  potency  is unaffected  by  long-term  storage  at  ambi-
ent  temperature  would  obviate  major  vaccine  deployment  hurdles  and  limit  wastage  associated  with
breaks  in  the  vaccine  cold  chain.  Here,  we evaluated  the  immunogenicity  of  a novel  chimpanzee  adeno-
virus  vectored  Rift  Valley  Fever  vaccine  (ChAdOx1-GnGc)  in cattle,  following  its  thermostabilisation  by






bilised  ChAdOx1-GnGc  vaccine  stored  for  6 months  at 25,  37 or 45 C elicited  comparable  Rift  Valley  Fever
virus  neutralising  antibody  titres  to those  elicited  by the  ‘cold  chain’  vaccine  (stored  at  −80 ◦C throughout)
at  the  same  dose,  and  these  were  within  the  range  associated  with  protection  against  Rift  Valley  Fever
in  cattle.  The  results  support  the  use  of sugar-membrane  thermostabilised  vaccines  in  target  livestock
species.
ublis©  2016  The  Authors.  P
. Introduction
Storage and deployment of vaccines whilst maintaining a cold
hain accounts for a major cost of effective human and veterinary
mmunisation programs. In resource-limited settings, where the
urden of vaccine-preventable illness is high and logistical chal-
enges such as lack of uninterrupted electricity supply and poor
ransport links abound, maintaining the vaccine cold chain is par-
icularly difﬁcult. Safe and efﬁcacious vaccines whose potency is
naffected by long-term storage at ambient temperature would
ubstantially reduce deployment costs, reduce vaccine wastage
hat occurs following breakdown of the cold chain and potentially
mprove vaccine coverage [1–3].
Adenoviruses are among the most promising platforms for
evelopment of safe, novel candidate vaccines against human
nd animal diseases. These non-enveloped double-stranded DNA
iruses have been adapted to produce replication-deﬁcient vac-
ine vectors and evaluated in humans and a wide range of animal
pecies, with excellent safety, immunogenicity and efﬁcacy against
any diverse pathogens [4–6]. However, like many other live
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vaccine vectors, adenoviruses are heat labile, necessitating cold
chain storage of vectored vaccines utilising the platform.
Previously, we  developed a thermostabilisation method termed
‘sugar-membrane technology’ for heat labile vaccines that involves
their formulation in a stabilising solution of nonreducing disac-
charides trehalose and sucrose, followed by drying onto ﬁbrous
membranes at ambient temperature to form an inert sugar-glass
that thinly coats the ﬁbrous membrane [7]. The impregnated mem-
branes allow storage of vaccine for long periods of time, with very
little loss of active material following reconstitution with liquid
buffer. Using this technology, a replication-deﬁcient adenovirus
vaccine encoding a malaria antigen was  previously stored at ambi-
ent temperature or 37 ◦C for 15 months and at 45 ◦C for up to
6 months, without signiﬁcant loss in viral titre or immunogenic-
ity [7]. However, this proof-of-concept study was  performed in
a mouse model and not in the target species for the disease (i.e.
humans).
Here, we determined whether a sugar-membrane thermosta-
bilised adenovirus vaccine could be deployed in an actual vaccine
target population. Our target disease was Rift Valley Fever, a
mosquito-borne viral zoonosis endemic in Africa and the Arabian
Peninsula caused by an enveloped negative-stranded RNA virus
[8]. The disease occurs as recurrent epizootics of febrile illness in
ruminants, with very high mortality rates in young sheep, goats
and cattle, and abortion in pregnant animals. Contact with animal
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
P. Dulal et al. / Vaccine 34 (2016) 2296–2298 2297
F ilised













































cig. 1. ChAdOx1-GnGc can readily be thermostabilised. In (a) the titre of thermostab
or  1 week, 1 month or 6 months at the indicated temperatures is shown. In (b), the
emperatures is shown. Dashed line represents the detection limit.
issues or body ﬂuids contaminated with Rift Valley Fever virus
RVFV) is a major route of infection for humans, in whom disease
rimarily occurs as a self-limiting febrile illness that occasionally
rogresses to severe manifestations associated with high (>30%)
ase fatality rates or debilitating sequelae [9–11]. No licensed vac-
ines are currently available for humans and the live RVFV virus
accines widely used for livestock in Africa have major drawbacks,
ncluding residual virulence, need for high containment during pro-
uction, and variable immunogenicity [12]. Furthermore, though
vailable as lyophilised products, the bioactivity of these live RVFV
ivestock vaccines still relies on a cold chain [12,13].
To address these issues, we previously developed ChAdOx1-
nGc, a replication-deﬁcient chimpanzee adenovirus vaccine
ncoding the RVFV envelope glycoproteins that are major targets
f a protective neutralising antibody response [14,15]. Unlike the
hole RVFV livestock vaccines in current use [12,16], ChAdOx1-
nGc contains only the protective immune targets of RVFV making
ts use compatible with readily available kits that distinguish
nfected from vaccinated animals on the basis of seropositivity for
ther RVFV antigens. This is a key consideration for effective dis-
ase control during outbreaks [12]. Single-dose immunisation with
hAdOx1-GnGc is highly immunogenic and provides 100% protec-
ion against RVFV challenge in sheep, goats and cattle [15], making
t a promising candidate for deployment in livestock and humans.
hus, we here evaluated the potency of thermostabilised ChAdOx1-
nGc vaccine in cattle and compared this with the ‘cold-chain’
ersion of vaccine used in these prior studies.
. Materials and methods
ChAdOx1-GnGc was prepared by Gateway® recombination
etween the ChAdOx1 destination vector and an entry plasmid
ontaining the coding sequence for RVFV envelope glycoproteins
Genbank accession number DQ380208, bases 411–3614) as
escribed [14]. Standard methods were used for viral rescue, propa-
ation in HEK293 cells and subsequent puriﬁcation by CsCl gradient
ltracentrifugation. The vaccine stock stored in production buffer
10 mM Tris, pH 7.4) at −80 ◦C was thawed and pooled together
o prepare a working stock. Infectivity titre of the working stock
as measured to be 3.15 × 1010 infectious units (IU)/ml. For ther-
ostabilisation, aliquots of the working stock were formulated in
n unbuffered 0.5 M solution containing a mixture of trehalose
nd sucrose, pipetted onto Whatman® S14 glass ﬁber (GF) mem-
ranes, and dried in a low relative humidity environment in a
rying chamber at ambient temperature [7]. No freeze-drying steps
ere involved. The dried ChAdOx1-GnGc-loaded GF membranes
ach contained approximately 5 × 108 IU of ChAdOx1-GnGc vac-
ine. These were placed in bijou vials (two 1 cm2 GF membranes ChAdOx1-GnGc vaccine following reconstitution in production buffer after storage
f ‘cold chain’ ChAdOx1-GnGc vaccine after storage for 1 week at the same range of
per vial), packaged in heat-sealed moisture barrier bags (Dri-Shield
3000, 3 M)  and stored at 25, 37, 45 or 55 ◦C for 6 months in heat
chambers equipped with temperature-monitoring probes. Com-
parisons of vaccine titre and vaccine-elicited immune responses
in cattle were then made between the storage conditions in rela-
tion to the control ‘cold chain’ ChAdOx1-GnGc vaccine (i.e. liquid
vaccine stored in production buffer at −80 ◦C). Animal experiments
were performed at the Pirbright Institute, UK in accordance with
institutional and national Home Ofﬁce guidelines.
3. Results and discussion
We ﬁrst examined the effect of thermostabilisation on vaccine
infectivity titre after storage at these temperatures. Thermosta-
bilised ChAdOx1-GnGc vaccine on GF membranes in each sample
vial was  reconstituted in 500 l production buffer after storage for
1 week, 1 month and 6 months. The infectious titre of the vaccine
was determined by an immunoassay on HEK293 cells as described
[17]. Consistent with our previous proof-of-concept study [7], we
were able to recover viable vaccine at all storage temperatures
and time points (Fig. 1a). In contrast, when storing the ‘cold chain’
ChAdOx1-GnGc vaccine in liquid form for 1 week at the same range
of temperatures, recovery of viable vaccine was only possible at
25 and 37 ◦C, with lower titres at the latter temperature (Fig. 1b).
Titres of the thermostabilised ChAdOx1-GnGc vaccine were com-
parable to the control ‘cold chain’ vaccine (i.e. stored at −80 ◦C
throughout) at the 1-week time point for all temperatures (Fig. 1a).
However, marked reduction in viability was  observed after storage
for 1 month at 55 ◦C, with a more than tenfold loss in titre observed
at 6 months.
Next, we determined the immunogenicity of the thermostable
ChAdOx1-GnGc vaccine in cattle, a major target species for a
Rift Valley Fever vaccine [12]. The immunogenicity endpoint was
induction of RVFV neutralising antibody as this is the main cor-
relate of protection [18,19]. Three-month old Holstein-Friesian
calves were sourced from commercial farms in the UK and ran-
domly allocated into six groups. Groups 1−4 received thermostable
ChAdOx1-GnGc vaccine (n = 4 per group) reconstituted from the GF
membranes in 1 ml  production buffer after storage for 6 months at
25, 37, 45 or 55 ◦C, respectively. Group 5 received the control ‘cold
chain’ ChAdOx1-GnGc vaccine (n = 4), whereas calves in group 6
(n = 2) were left unvaccinated. All vaccinations were intramuscu-
larly administered as a single dose on the right hind limb. Blood for
immunological assays was sampled pre-vaccination and at week 4
post-vaccination, after which all animals were culled.
No local (swelling, pruritus or erythema) or systemic (inap-
petance, or other clinical signs) adverse events were observed
among any of the animals following vaccination. Two  calves, one
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Fig. 2. Thermostabilised ChAdOx1-GnGc elicits functional antibody. The titre of
RVFV neutralising antibody elicited by vaccination with thermostabilised ChAdOx1-
GnGc following 6 months storage at the indicated temperatures is shown. Brieﬂy,
sera were heat-inactivated at 56 ◦C for 30 min  and serially diluted in quadrupli-
cate in buffer before incubation with 100TCID50 of RVFV MP-12 strain for 60 min
at  37 ◦C. This serum-virus mixture was then transferred onto conﬂuent Vero cell
monolayers, incubated at 37 ◦C and 5% CO2 for 72 h, ﬁxed and stained, and endpoint
titres calculated by the Spearman-Karber method as described [15]. Data represent



































[omparison by the Kruskal−Wallis test is shown. The 55 ◦C and unvaccinated (con-
rol) groups had no detectable response and are excluded from this analysis.
n the ‘cold chain’ vaccine group and the other in the 37 ◦C group,
eveloped unrelated respiratory illness during the course of follow
p and were culled before the end of the study. With the exception
f calves receiving vaccine stored at 55 ◦C, all vaccinees mounted
 functional antibody response able to neutralise live RVFV in vitro
Fig. 2). Though slightly variable between groups there was no
vidence for a statistically signiﬁcant difference between the neu-
ralising antibody titres elicited by the thermostable and ‘cold
hain’ vaccines (Kruskal-Wallis test p = 0.2), and the titres were
ithin the range associated with protection against RVFV in cattle
Fig. 2) [15].
Together, the results further support the utility of the sugar-
embrane technology in thermostabilising adenovirus-vectored
accines. Though these viral vectors have been utilised in human
nd animal vaccines against a wide range of pathogens [4,5,20],
his is to our knowledge the ﬁrst assessment of a thermostabilised
denovirus-vectored vaccine in a vaccine target population. Further
valuation of the sugar-membrane thermostabilised ChAdOx1-
nGc vaccine in ﬁeld efﬁcacy studies involving large numbers of
ivestock in RVFV-endemic settings in Africa is clearly warranted.
uch studies will allow a cost-beneﬁt analysis of the manufacture,
ormulation and use of the thermostable product in comparison
o the ‘cold chain’ ChAdOx1-GnGc vaccine and provide useful end-
ser data on its suitability for ﬁeld deployment.onﬂict of interest
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